The Use (or rather the non-Use) of Cost-Effectiveness Data in Priority Setting Decisions – Are We Underestimating the Barriers to Using Health Economics in Real World Priority Setting Decisions?; Comment on “Use of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden”

Document Type : Commentary


LEO Pharma A/S, Copenhagen, Denmark


After having practicing and researching health economics for nearly 15 years now, it has become clear to me that the use of cost-effectiveness data in priority setting decisions is rather a rare than a common practice. The Eckard et al.article though, describes a wonderful exception to this rule and a very good example of how it can be used when the conditions are right. However, do we fully understand what these conditions are? In this commentary article I will address some of the institutional and cultural conditions that need to be fulfilled in order for cost-effectiveness data to actually be used in priority setting decisions.


Main Subjects

  1. Coyle D.  Increasing the Impact of Economic Evaluations in Health-Care Decision Making. Discussion paper 108. Centre for Health Economics, University of York, Health Economics Consortium; 1993.
  2. Drummond M, Cooke J, Walley T. Economic Evaluation in Health Care Decision Making: Evidence from the UK. Discussion paper 148. Centre for Health Economics, University of York, Health Economics Consortium; 1996.
  3. Späth HM, Charavel M, Morelle M, Carrere MO. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm World Science 2003 25: 269-75. doi: 10.1023/b:phar.0000006523.22131.69
  4. McDonald R.  Using Health Economics in Health Services. Rationing Rationally? Buckingham: Open University Press; 2002
  5. Suh DC, Okpara IR, Agnese WB, Toscani M. Application of Pharmacoeconomics to Formulary Decision Making in Managed Care Organizations. Am J Manag Care 2002; 8: 161-9.
  6. Van Velden ME, Severens JL, Novak A. Economic Evaluations of Healthcare Programmes and Decision Making. Pharmacoeconomics  2005; 23: 1075-82. doi: 10.2165/00019053-200523110-00002
  7. Walkom E, Robertson J, Newby D, Pillay T. The role of pharmacoeconomics in formulary decision-making. Considerations for hospital and managed care pharmacy and therapeutics committees. Formulary 2006 41: 374-86.
  8. Williams I, Bryan S, McIver S. The use of health economic evaluations in NHS decision-making. A review and empirical investigation. Health Technology Assessment  2008; 12(7). Available from:
  9. Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy2008; 86: 129-41.  doi: 10.1016/j.healthpol.2007.11.010
  10. Vourenkoski L, Toivaninen H, Hemminki E. Decision-making in priority setting for medicines – A review of empirical studies. Health Policy 2008; 86: 1-9. doi: 10.1016/j.healthpol.2007.09.007
  11. Anell A. Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees. Eur J Health Econ 2004; 5: 28-35. doi: 10.1007/s10198-003-0195-0
  12. Eckard N, Janzon M, Levin LÅ. Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden. Int J Health Policy Manag 2014; 3: 323-32. doi: 10.15171/ijhpm.2014.105
  13. 13.   Erntoft S. The use of health economic evaluations in pharmaceutical priority setting. The case of Sweden [Doctoral dissertation]. Lund Business Press, Lund Institute of Economic Research, Lund University; 2010.
  14. Daniels N, Sabin J. Limits to Health Care: Fair Procedures, Democratic Deliberation, and the Legitimacy Problem for Insurers. Philos Public Aff 1997; 26: 302-50. doi: 10.1111/j.1088-4963.1997.tb00082.x
  15. DiMaggio P, Powell WW. The iron cage revisited: Institutional Isomorphism and Collective Rationality in Organizational Fields. Am Soc Rev 1983; 48: 147-60. doi: 10.2307/2095101
  16. 16.   Williams I. Cost-effectiveness analysis and technology coverage decision making: the case of the English NHS [Doctoral dissertation]. HealthServices Management Centre, School of Social Policy, University ofBirmingham; 2009.